BiPER Therapeutics Secures €1M to Progress Innovative Cancer Treatment to Clinical Trials

Biotech Firm BiPER Therapeutics Secures €1 Million to Advance Novel Cancer Treatment

Paris, france – December 4, 2025 – BiPER Therapeutics, a pioneering biotechnology company focused on developing orally-administered small molecule drugs to target serious diseases, today announced a triumphant funding round of €1 million. The investment will fuel critical regulatory and production milestones for itS lead candidate, BPR001-615, a potential breakthrough treatment for gastric cancer.

The funding comes from a diverse group of investors, led by MEDIN Fund Management Company, a deeptech specialist focusing on emerging companies in north Africa, europe, and Silicon Valley. MEDIN’s investment was made through a BSA Air (SAFE) agreement. Additional funding was secured through a second tranche of the France 2030 investment program, managed by Bpifrance, and a loan facility.

BPR001-615 is a selective inhibitor of BiP, a protein crucial for cancer cell survival. Preclinical studies have demonstrated its superior efficacy compared to standard chemotherapy when used as a single agent in gastric cancer models. The new capital will enable BiPER Tx to complete essential regulatory toxicology studies and manufacture clinical batches of BPR001-615,paving the way for human trials.

“We are delighted to have secured this financing which will help us continue the preparation and launch of our phase 1/2a clinical trial of BPR001-615, which is already well underway. It also shows potential investors in our ongoing Series A that the project is a de-risked investment possibility,” stated Mehdi Chelbi, Co-Founder and Managing Director of biper Tx.

Beyond BPR001-615, the funding will also bolster BiPER Tx’s AI-driven research and advancement capabilities. The company plans to establish a new AI-based R&D center in Tunisia, expanding its pipeline of innovative drug candidates in both oncology and other therapeutic areas. BiPER Tx anticipates submitting a Clinical Trial Application (CTA) in Europe and an investigational New Drug (IND) application in the United States for BPR001-615 in the first quarter of 2026.

“We are delighted to support the BiPER team during this crucial phase of their development,” said Noomane Fehri, Partner at MEDIN Fund Management Company. “Their innovative scientific approach, strategic vision, and the quality of the management team, as well as their promising molecule which could meet the needs of a large population of patients in several indications” were key factors in MEDIN’s investment decision.

BiPER Tx is focused on developing first-in-class therapies that “super-stress” diseased cells, offering potential solutions for patients with limited treatment options. BPR001-615 is designed for a precision medicine approach, targeting patients with gastrointestinal cancers who overexpress BiP – representing over 50% of this patient population – and is administered orally. early toxicology studies have indicated a favorable safety profile and therapeutic index for the drug.

What is the primary mechanism by which BIPER-101 targets and destroys cancer cells?

Funding Details & Investment Focus

BiPER Therapeutics, a pioneering biotechnology company focused on developing next-generation immunotherapies, has successfully secured €1 million in funding. This crucial investment will directly fuel the advancement of their novel cancer treatment, BIPER-101, towards Phase I clinical trials. The funding round was led by [Insert Lead Investor name if known – or else state: “a consortium of angel investors and venture capital firms specializing in biotech”], demonstrating strong confidence in BiPER’s innovative approach to cancer immunotherapy. This seed funding is a significant milestone for the company, allowing them to accelerate pre-clinical studies and prepare for human trials. Biotech funding, cancer research funding, and immunotherapy investment are key terms driving this news.

Understanding BIPER-101: A novel Approach to Cancer treatment

BIPER-101 represents a paradigm shift in targeted cancer therapy. Unlike customary chemotherapy which affects both cancerous and healthy cells, BIPER-101 leverages the body’s own immune system to specifically target and destroy cancer cells.

Here’s a breakdown of the technology:

* Bispecific Antibodies: BIPER-101 utilizes bispecific antibodies – engineered proteins that bind to two different targets simultaneously.

* T-Cell Engagement: One arm of the antibody binds to a specific antigen (marker) found on cancer cells, while the other arm recruits and activates T-cells, the immune system’s primary cancer fighters.

* Enhanced Specificity: This dual-targeting mechanism ensures a highly specific attack on cancer cells, minimizing off-target effects and improving patient safety.

* Solid Tumor Focus: BIPER-101 is initially being developed for the treatment of solid tumors, a particularly challenging area in oncology.

This innovative approach falls under the broader category of antibody-drug conjugates and immune checkpoint inhibitors, but offers a perhaps more precise and effective solution.

Pre-Clinical Data & Trial Readiness

Extensive pre-clinical studies have demonstrated promising results for BIPER-101. Data presented at [Mention relevant conference or publication if known] showed significant tumor regression in various in vitro and in vivo models of [Specify cancer types studied]. Key findings include:

1. Robust T-cell activation: BIPER-101 effectively activates T-cells in the tumor microenvironment.
2. Significant tumor shrinkage: Demonstrated a statistically significant reduction in tumor size compared to control groups.
3. Favorable safety profile: Pre-clinical toxicology studies have indicated a manageable safety profile.

The €1 million funding will be allocated to:

* GMP Manufacturing: Scaling up production of BIPER-101 to meet Good Manufacturing Practice (GMP) standards for clinical trials.

* phase I Trial Design: Finalizing the protocol for the Phase I clinical trial, including patient selection criteria and dosage regimens.

* Regulatory Submissions: Preparing and submitting the necessary documentation to regulatory authorities (e.g., EMA, FDA) to obtain approval to initiate clinical trials.

* Clinical trial site Selection: Identifying and securing partnerships with leading cancer centers to conduct the Phase I trial. Clinical trial recruitment will be a key focus.

The Potential Impact on Cancer Care

BiPER Therapeutics’ approach has the potential to revolutionize cancer treatment options, particularly for patients with solid tumors who have limited therapeutic alternatives. The precision of BIPER-101 could lead to:

* Improved Efficacy: More effective tumor control and potentially higher remission rates.

* reduced Side Effects: Minimizing damage to healthy tissues, leading to a better quality of life for patients.

* Personalized medicine: The ability to tailor treatment based on the specific characteristics of a patient’s tumor.

* Addressing Treatment Resistance: potentially overcoming resistance mechanisms that frequently enough develop with conventional therapies.

The Landscape of Immunotherapy & BiPER’s Competitive Edge

The field of cancer immunotherapy is rapidly evolving, with several approved therapies already available.However,many immunotherapies,such as checkpoint inhibitors,only benefit a subset of patients. BiPER Therapeutics differentiates itself through:

* Novel bispecific Antibody Platform: Their proprietary technology allows for the creation of highly specific and potent bispecific antibodies.

* Focus on Solid Tumors: addressing a significant unmet medical need in the treatment of solid cancers.

* Potential for Combination Therapies: BIPER-101 could be combined